Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Anemia is a prevalent and multifactorial complication of chronic kidney disease (CKD), often driven by inflammation, impaired iron metabolism, and reduced erythropoietin production. Lactoferrin, an iron-binding glycoprotein with immunomodulatory and antimicrobial properties, has demonstrated efficacy in improving iron indices in general iron deficiency anemia. However, its role in CKD-associated anemia remains inadequately characterized.
A systematic review and meta-analysis were conducted to evaluate the effectiveness of oral lactoferrin compared to standard-of-care therapies—including iron supplementation and/or erythropoiesis-stimulating agents—for the treatment of anemia in adult and pediatric CKD patients. PubMed, Embase, and Cochrane CENTRAL were searched through May 7, 2025. Data were pooled using a random-effects model, and heterogeneity was assessed using the I² statistic. Sensitivity analyses and trial sequential analysis (TSA) were performed to assess robustness and adequacy of cumulative evidence.
Four studies comprising 413 participants were included in the final analysis. Lactoferrin supplementation was associated with a statistically significant increase in transferrin saturation (MD: 8.12%; 95% CI: [0.61, 15.63]; p = 0.03), while improvements in hemoglobin (MD: 0.66 g/dL; 95% CI: [-0.06, 1.38]; p = 0.07) and serum iron (MD: 19.20 mcg/dL; 95% CI: [-4.56, 42.96]; p = 0.11) did not reach statistical significance.
Oral lactoferrin supplementation was associated with a significant improvement in transferrin saturation and a non-significant trend toward higher hemoglobin and serum iron levels in CKD-related anemia. While these findings suggest a potential role in improving functional iron availability, further well-designed trials are needed to confirm its clinical utility.
